Sleep Apnea-hypopnea Syndrome (SAHS) and Ventricular Arrhythmias (SAHS-ICD)

This study has been completed.
Sponsor:
Collaborators:
Hospital Virgen de la Salud
Hospital Virgen de la Macarena
Information provided by:
Hospital Universitario La Paz
ClinicalTrials.gov Identifier:
NCT00765713
First received: October 2, 2008
Last updated: April 1, 2013
Last verified: September 2008

October 2, 2008
April 1, 2013
October 2008
October 2012   (final data collection date for primary outcome measure)
Number of appropriate defibrillator therapies [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00765713 on ClinicalTrials.gov Archive Site
AHI, incidence of premature ventricular beats and non-sustained ventricular tachycardia. Plasmatic levels of C-reactive protein, homocystein, pro-BNP, sTNFαR-I, IL-1b, IL-2, IL-6, IL-8, IL-8 and 8-isoprostane [ Time Frame: 24 moths ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Sleep Apnea-hypopnea Syndrome (SAHS) and Ventricular Arrhythmias
Sleep Apnea-hypopnea Syndrome and Ventricular Arrhythmias in Patients With Systolic Ventricular Dysfunction and Implantable Cardioverter-defibrillator. Incidence and Effect of CPAP Treatment

Hypothesis:

The CPAP treatment diminishes the effect of ventricular arrhythmias in patients with ischemic heart disease or dilated myocardiopathy, systolic ventricular disfunction and sleep apnea-hypopnea syndrome (SAHS)Objectives: To analyze the incidence of ventricular arrhythmias (premature ventricular beat, non-sustained ventricular tachycardia and sustained ventricular tachycardia) and appropriate defibrillator therapies in patients with ischemic heart disease or dilated myocardiopathy, moderate-severe left ventricular dysfunction,with an implantable cardioverter-defibrillator (ICD) and sleep apnea. To study the effect of CPAP on the cardiac arrhythmias and on the number of appropriate defibrillator therapies.

Design:

Parallel, randomized and single-blinded multicentric study to compare CPAP vs. hygienic-dietetic recommendations.

Patients with SAHS (AHI≥15) and systolic left ventricle dysfunction patients with an ICD.

Duration: 24 months.

Secondary objectives:

To compare the prevalence of SAHS in patients with ischemic heart disease or dilated myocardiopathy and moderate-severe left ventricle dysfunction with ICD with that of the general population. To study the incidence of supraventricular arrhythmias (atrial fibrillation, atrial flutter or supraventricular tachycardia) and inappropriate defibrillator therapies in these patients. To value the effect of the treatment with CPAP on the above mentioned arrhythmias. To relate the effect of ventricular and supraventricular arrhythmias with sleep parameters, cardiovascular biomarkers, inflammation and oxidative stress. To evaluate the long-term effect of the CPAP on systemic biomarkers in patients with ischemic heart disease or dilated myocardiopathy and moderate-severe left ventricle dysfunction. To evaluate the long-term effect of CPAP on the quality of life in these patients.

Sample size:

224 patients with ischemic heart disease or dilated myocardiopathy and moderate-severe left ventricle dysfunction with ICD will be included to randomize 19 SAHS subjects for arm.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
  • Sleep Apnea
  • Ventricular Arrythmias
  • Systolic Left Ventricle Dysfunction
Device: Nasal continuous positive airway pressure
Nocturnal
  • Experimental: CPAP
    Continuous positive airway pressure
    Intervention: Device: Nasal continuous positive airway pressure
  • No Intervention: Conventional
    Hygienic-dietetic recommendations
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
224
January 2013
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Previous diagnostic of ischaemic heart disease of dilated myocardiopathy
  • Ejection fraction of left ventricle < 40%
  • Patients with implantable cardioverter-defibrillator

Exclusion Criteria:

  • Diurnal hypersomnolence with EES > 16
  • Morbid obesity (BMI > 35 Kg/m2).
  • Moderate-severe chronic obstructive pulmonary disease (FEV1/FVC < 70 % and FEV1 < 80 % of reference).
  • Known thyroid disease.
  • Previous treatment with CPAP.
Both
18 Years to 75 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT00765713
HULP PI-719
No
Rafael Peinado Peinado, Hospital Universitario La Paz
Hospital Universitario La Paz
  • Hospital Virgen de la Salud
  • Hospital Virgen de la Macarena
Study Director: Francisco Garcia-Rio, PhD Hospital Universitario La Paz
Hospital Universitario La Paz
September 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP